News

Hosted on MSN4mon
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release.
NPR4mon
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray ... of about $780 million for its maker, Johnson & Johnson. Spravato is intended to ...
pharmaphorum3d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.
AOL4mon
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom improvement." The nasal spray was first approved by the ...